Cytodyn Inc
Change company Symbol lookup
Select an option...
CYDY Cytodyn Inc
HRZN Horizon Technology Finance Corp
IZEA IZEA Worldwide Inc
HAIIF Haitian International Holdings Ltd
PM Philip Morris International Inc
CCLP CSI Compressco LP
CBWTF Auxly Cannabis Group Inc
FGPR Ferrellgas Partners LP
PFE Pfizer Inc
MSFT Microsoft Corp
Go

Health Care : Biotechnology |
Company profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Price
Delayed
$4.88
Day's Change
-0.094 (-1.89%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.08
Day's Low
4.70
Volume
(Light)

Today's volume of 2,772,699 shares is on pace to be much lighter than CYDY's 10-day average volume of 6,678,742 shares.

2,772,699

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors

6:00 pm ET July 1, 2020 (BusinessWire) Print

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of CytoDyn Inc. ("CytoDyn" or the "Company") (OTC: CYDY) investors concerning the Company and its officers' possible violations of the federal securities laws.

If you suffered a loss on your CytoDyn investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/cytodyn-inc/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On April 27, 2020, CytoDyn issued a press release indicating it had submitted a "Biologics License Application ('BLA') to the U.S. Food and Drug Administration for Leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients."

Then, on May 7, 2020, CytoDyn announced that its BLA for Leronlimab "will be considered completed after the clinical datasets are submitted on May 11, 2020."

On this news, the Company's share price fell as much as $0.225, or more than 7%, during intraday trading on May 8, 2020.

On June 30, 2020, Citron Research issued a report stating, among other things, that despite CytoDyn's "aggressively tout[ing] its investigational drug candidate, Leronlimab, as a potential treatment for COVID-19 . . . there is zero scientific data to support this view."

On this news, the Company's share price fell $3.09, or over 35%, to close at $5.68 per share on June 30, 2020, on unusually heavy trading volume.

Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice: Persons with non-public information regarding CytoDyn should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward-looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM's attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005817/en/

SOURCE: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com 
shareholders@glancylaw.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.